A
Arnon Nagler
Researcher at Sheba Medical Center
Publications - 1435
Citations - 51740
Arnon Nagler is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 98, co-authored 1316 publications receiving 44298 citations. Previous affiliations of Arnon Nagler include French Institute of Health and Medical Research & University of Paris.
Papers
More filters
Journal ArticleDOI
MT1-MMP and RECK are involved in human CD34+ progenitor cell retention, egress, and mobilization
Yaron Vagima,Abraham Avigdor,Abraham Avigdor,Polina Goichberg,Shoham Shivtiel,Melania Tesio,Alexander Kalinkovich,Karin Golan,Ayelet Dar,Orit Kollet,Isabelle Petit,Orly Perl,Ester Rosenthal,Igor B. Resnick,Izhar Hardan,Yechiel N. Gellman,David Naor,Arnon Nagler,Tsvee Lapidot +18 more
TL;DR: The results reveal that the motility, adhesion, homing, and mobilization of human hematopoietic progenitor cells are regulated in a cell-autonomous manner by dynamic and opposite changes in MT1-MMP and RECK expression.
Journal ArticleDOI
Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma.
Nicolaus Kröger,Avichai Shimoni,Maria Zagrivnaja,Francis Ayuk,Michael Lioznov,Heike Schieder,Helmut Renges,Boris Fehse,Tatjana Zabelina,Arnon Nagler,Axel R. Zander +10 more
TL;DR: Adoptive immunotherapy with low-dose thalidomide and DLI induces a strong antimyeloma effect with low incidence of graft versus host disease.
Journal ArticleDOI
Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003.
Michal Abraham,Katia Biyder,Michal Begin,Hanna Wald,Ido D. Weiss,Eithan Galun,Arnon Nagler,Amnon Peled +7 more
TL;DR: It is found that the CXCR4 antagonist known as 4F‐benzoyl‐TN14003 (T‐140) can induce mobilization of hematopoietic stem cells and progenitors within a few hours post‐treatment in a dose‐dependent manner.
Journal ArticleDOI
Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study
Roni Shouval,Roni Shouval,Myriam Labopin,Ori Bondi,Hila Mishan-Shamay,Avichai Shimoni,Fabio Ciceri,Jordi Esteve,Sebastian Giebel,Norbert Claude Gorin,Christoph Schmid,Emmanuelle Polge,Mahmoud Aljurf,Nicolaus Kröger,Charles Craddock,Andrea Bacigalupo,Jan J. Cornelissen,Frédéric Baron,Ron Unger,Arnon Nagler,Mohamad Mohty +20 more
TL;DR: The alternating decision tree model provides a robust tool for risk evaluation of patients with AL before HSCT, and is available online as a continuous probabilistic score for the prediction of day 100 OM, extending prediction to 2 years.
Journal ArticleDOI
Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma.
Nicolaus Kröger,Bronwen E. Shaw,Simona Iacobelli,Tatjana Zabelina,Karl S. Peggs,Avichai Shimoni,Arnon Nagler,Thomas M.C. Binder,Thomas Eiermann,Alejandro Madrigal,Rainer Schwerdtfeger,Michael G. Kiehl,Herbert G. Sayer,Jörg Beyer,Martin Bornhäuser,Francis Ayuk,Axel R. Zander,David I. Marks +17 more
TL;DR: It is concluded that alemtuzumab produced less acute GvHD, but higher probability of relapse, and implicated a major role of KIR‐ligand mismatched transplantation in multiple myeloma.